Results 71 to 80 of about 12,787 (210)

Neurological Complications After Pediatric Liver and Kidney Transplantation: A Comprehensive Review of Acute Symptomatic Seizures

Pediatric Transplantation, Volume 30, Issue 5, May 2026.
ABSTRACT Acute symptomatic seizures (ASS) represent one of the most frequent and clinically significant neurological complications following pediatric liver and kidney transplantation. Despite their clinical relevance, available evidence remains fragmented; pediatric‐specific data are limited, and no standardized diagnostic or management framework has ...
Semash Konstantin, Dzhanbekov Timur, Nasirov Mansur, Umarov Bakhtiyorjon, Qambarov Navruz, Khamdamov Bakhtiyor   +5 more
wiley   +1 more source

Multiple Myeloma as the Underlying Cause of Thrombotic Microangiopathy Leading to Acute Kidney Injury: Revisiting a Very Rare Entity

Journal of Investigative Medicine High Impact Case Reports, 2017
Thrombotic microangiopathy (TMA) describes a pathological process of microvascular thrombosis, consumptive thrombocytopenia, and microangiopathic hemolytic anemia, leading to end-organ ischemia and infarction, affecting particularly the kidney and brain.
Savneek Chugh MD, Asim Kichloo MD, Firas Jafri MD, Liga Yusvirazi MD, Robert Lerner MD   +4 more
doaj   +1 more source

An Atypical Cause Of Atypical Hemolytic Uremic Syndrome

Marshall Journal of Medicine, 2016
Atypical hemolytic syndrome is an extremely rare, life threatening, progressive disease. Approximately one to two cases per million are seen annually in the US (3,4).
Abhinav Sharma, Carolina de Elia, Eric Arguelles , Christine L. Gilkerson   +3 more
doaj   +1 more source

The Complement System in Post‐Transplant Kidney Injury

Organ Medicine, EarlyView.
Mengsi Hu
wiley   +1 more source

Síndrome Hemolítico Urémico Atípico en Cuidados Intensivos: Caso Clínico de un Adulto [PDF]

, 2016
info:eu-repo/semantics ...
Agudo, I, Azevedo, L, Bento, L, Cavaco, R, Germano, N, Souto-Moura, T   +5 more
core   +1 more source

Inhibition of Classical and Alternative Complement Pathway by Ravulizumab and Eculizumab

Annals of Clinical and Translational Neurology, Volume 13, Issue 4, Page 688-699, April 2026.
ABSTRACT Objective To explore the feasibility of classical (CH50) and alternative (AH50) complement pathway activity as potential biomarkers for treatment guidance and monitoring during therapy with ravulizumab in patients with generalized myasthenia gravis (gMG) and compare these to therapeutic drug monitoring under eculizumab.
Lea Gerischer, Frauke Stascheit, Maximilian Mönch, Paolo Doksani, Carla Dusemund, Meret Herdick, Philipp Mergenthaler, Maike Stein, Amani Suboh, Jutta Schröder‐Braunstein, Guido Wabnitz, Jan D. Lünemann, Sophie Lehnerer, Sarah Hoffmann, Andreas Meisel   +14 more
wiley   +1 more source

Biopharmaceuticals for Cancer Treatment: An Update

Cancer Medicine, Volume 15, Issue 4, April 2026.
ABSTRACT Cancer is one of the most debilitating diseases, causing profound physical and psychological impacts on patients. The global number of cancer patients has been steadily rising over the last few decades. The development of effective cancer therapies remains the primary focus in life science research, requiring a precise understanding of ...
Anupom Deb Nath, Yousuf Alam, Afsana Mustak Mim, Maksuda Akter, Mohammad Abbas Gani, Khondaker Muhammad Khairul Alam, Md. Nur Alam   +6 more
wiley   +1 more source

Eculizumab safely reverses neurologic impairment and eliminates need for dialysis in severe atypical hemolytic uremic syndrome

Clinical Pharmacology: Advances and Applications, 2011
Maro Ohanian, Christian Cable, Kathleen HalkaDepartment of Hematology and Oncology, Scott and White Healthcare, The Texas A&M Health Science Center College of Medicine, Temple, TX, USAAbstract: This case report describes how eculizumab reversed ...
Ohanian M, Cable CC, Halka KK
doaj  

Atypical haemolytic-uraemic syndrome caused by factor H mutation: case report and new management strategies in children [PDF]

, 2012
Atypical haemolytic uraemic syndrome is causedby alternative complement pathway dysregulation. It has recently been recognised that most cases are due to genetic factors and a growing list of mutations has been described.
Araújo, L., Barbot, J., Costa, T., Faria, M., Mota, C., Rocha, L.   +5 more
core  

Properdin and factor H: Opposing players on the alternative complement pathway "see-saw" [PDF]

, 2013
This article has been made available through the Brunel Open Access Publishing Fund.Properdin and factor H are two key regulatory proteins having opposite functions in the alternative complement pathway.
Abdul-Aziz, M, Kishore, U, Kouser, L, Nayak, A, Sim, RB, Stover, CM   +5 more
core   +1 more source